In June, Novartis released multiple trial results of Consentyx (secukinumab) across all its three indications.
On 26, 2019 Novartis released the publication results showing rapid suppression of IL-23 and control of inflammation by Consentiyx in patients with plaque psoriasis. Cosentyx reduced the inflammation by modulating gene expression. Cosentyx has an effect on IL-23 and IL-17F.
On June 17, 2019, Novartis presented the long term safety data of Consentyx across multiple indications including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The abstract highlighted the long term immunogenicity of Cosentyx in Phase III extension studies (CAIN457A2304 and CAIN457A2307) in patients with moderate to severe plaque psoriasis.
On June 12, Novartis released data of two years of Cosentyx in patients with psoriatic arthritis. The study showed that 90% of patients on Cosentyx has no radiological progression of psoriatic arthritis. The patients were indicated with 300 mg of Consentyx.
On the same day, Consentyx released the results of MAXIMISE trial. The data showed the improvement in all axial manifestations of psoriatic arthritis. Phase IIIb trial met both primary and secondary endpoints. 63.1% of patients on 150 mg of Consentyx achieved ASAS20 at week 12.